Advertisement

Intensive Care Medicine

, Volume 41, Issue 3, pp 517–520 | Cite as

Understanding ARDS-associated fibroproliferation

  • Gianfranco Umberto MeduriEmail author
  • Mahmoud A. Eltorky
Understanding the Disease

Understanding ARDS-associated lung fibroproliferation requires viewing (1) ARDS as a disease of multifactorial etiology and not as a syndrome and (2) fibroproliferation as an integral part of the disease process and not as a separate temporal component. Although the term “syndrome” (aggregate of symptoms and signs) was applied in its original description [1], ARDS meets all the constitutive elements of a disease process [2]. Translational clinical research has constructed—through a “holistic” level of inquiry—a pathophysiological model of ARDS that fits the pathogenesis (biology—core stratum) with morphological (histology—intermediate stratum) and clinical (physiology—outer stratum) findings observed during the course of the disease [3].

Fibroproliferation is an integral component of the tissue defense response (TDR), a stereotypical host reaction to contain—at the tissue level—insults and repair any resultant injury. The TDR (constituent of innate immunity) consists of a highly...

Keywords

Diffuse Alveolar Damage Pulmonary Lobule Alveolar Duct Respiratory Bronchiole Vascular Surface 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

This material is the result of work supported with the resources and use of facilities at the Memphis VA Medical Center. The contents of this commentary do not represent the views of the US Department of Veterans Affairs or the United States Government.

Conflicts of interest

Both authors declare no conflicts of interest.

References

  1. 1.
    Ashbaugh DG, Bigelow DB, Petty TL, Levine BE (1967) Acute respiratory distress in adults. Lancet 2:319–323CrossRefPubMedGoogle Scholar
  2. 2.
    Kumar V, Abbas A, Fausto N, Aster J (2010) Cellular response to stress and toxic insults: adaptation, injury and, death. In: Kumar V, Abbas A, Fausto N, Aster J (eds) Robbins and Cotran Pathologic basis of disease. W.B. Saunders, Philadelphia, pp 3–42Google Scholar
  3. 3.
    Meduri GU, Annane D, Chrousos GP, Marik PE, Sinclair SE (2009) Activation and regulation of systemic inflammation in ARDS: rationale for prolonged glucocorticoid therapy. Chest 136:1631–1643CrossRefPubMedGoogle Scholar
  4. 4.
    Friedman R, Hughes AL (2002) Molecular evolution of the NF-kappaB signaling system. Immunogenetics 53:964–974CrossRefPubMedGoogle Scholar
  5. 5.
    Meduri GU, Muthiah MP, Carratu P, Eltorky M, Chrousos GP (2005) Nuclear factor-kappaB- and glucocorticoid receptor alpha-mediated mechanisms in the regulation of systemic and pulmonary inflammation during sepsis and acute respiratory distress syndrome. Evidence for inflammation-induced target tissue resistance to glucocorticoids. Neuroimmunomodulation 12:321–338CrossRefPubMedGoogle Scholar
  6. 6.
    Meduri GU, Eltorky M, Winer-Muram HT (1995) The fibroproliferative phase of late adult respiratory distress syndrome. Semin Respir Infect 10:154–175PubMedGoogle Scholar
  7. 7.
    Katzenstein AL, Bloor CM, Leibow AA (1976) Diffuse alveolar damage—the role of oxygen, shock, and related factors. A review. Am J Pathol 85:209–228PubMedCentralPubMedGoogle Scholar
  8. 8.
    Thille AW, Esteban A, Fernandez-Segoviano P, Rodriguez JM, Aramburu JA, Vargas-Errazuriz P, Martin-Pellicer A, Lorente JA, Frutos-Vivar F (2013) Chronology of histological lesions in acute respiratory distress syndrome with diffuse alveolar damage: a prospective cohort study of clinical autopsies. Lancet Respir Med 1:395–401CrossRefPubMedGoogle Scholar
  9. 9.
    Ichikado K, Muranaka H, Gushima Y, Kotani T, Nader HM, Fujimoto K, Johkoh T, Iwamoto N, Kawamura K, Nagano J, Fukuda K, Hirata N, Yoshinaga T, Ichiyasu H, Tsumura S, Kohrogi H, Kawaguchi A, Yoshioka M, Sakuma T, Suga M (2012) Fibroproliferative changes on high-resolution CT in the acute respiratory distress syndrome predict mortality and ventilator dependency: a prospective observational cohort study. BMJ open 2:e000545CrossRefPubMedCentralPubMedGoogle Scholar
  10. 10.
    Meduri GU, Tolley EA, Chinn A, Stentz F, Postlethwaite A (1998) Procollagen types I and III aminoterminal propeptide levels during acute respiratory distress syndrome and in response to methylprednisolone treatment. Am J Respir Crit Care Med 158:1432–1441CrossRefPubMedGoogle Scholar
  11. 11.
    Meduri GU (1996) The role of the host defence response in the progression and outcome of ARDS: pathophysiological correlations and response to glucocorticoid treatment. Eur Respir J 9:2650–2670CrossRefPubMedGoogle Scholar
  12. 12.
    Cordier J-F, Peyrol S, Loire R (1994) Bronchiolitis obliterans organizing pneumonia as a model of inflammatory lung disease. In: Epler GR (ed) Diseases of the Bronchioles. Raven Press Ltd, New York, pp 313–345Google Scholar
  13. 13.
    Burnham EL, Janssen WJ, Riches DW, Moss M, Downey GP (2014) The fibroproliferative response in acute respiratory distress syndrome: mechanisms and clinical significance. Eur Respir J 43:276–285CrossRefPubMedCentralPubMedGoogle Scholar
  14. 14.
    Conway Morris A, Kefala K, Wilkinson TS, Dhaliwal K, Farrell L, Walsh T, Mackenzie SJ, Reid H, Davidson DJ, Haslett C, Rossi AG, Sallenave JM, Simpson AJ (2009) C5a mediates peripheral blood neutrophil dysfunction in critically ill patients. Am J Respir Crit Care Med 180:19–28CrossRefPubMedGoogle Scholar
  15. 15.
    Meduri GU (2002) Clinical review: a paradigm shift: the bidirectional effect of inflammation on bacterial growth. Clinical implications for patients with acute respiratory distress syndrome. Crit Care 6:24–29CrossRefPubMedCentralPubMedGoogle Scholar
  16. 16.
    Serhan CN, Savill J (2005) Resolution of inflammation: the beginning programs the end. Nat Immunol 6:1191–1197CrossRefPubMedGoogle Scholar
  17. 17.
    Ware LB, Matthay MA (2000) The acute respiratory distress syndrome. N Engl J Med 342:1334–1349CrossRefPubMedGoogle Scholar
  18. 18.
    Forel JM, Guervilly C, Hraiech S, Voillet F, Thomas G, Somma C, Secq V, Farnarier C, Payan MJ, Donati SY, Perrin G, Trousse D, Dizier S, Chiche L, Baumstarck K, Roch A, Papazian L, (2015) Type III procollagen is a reliable marker of ARDS-associated lung fibroproliferation. Intensive Care Med 41:1–11CrossRefPubMedGoogle Scholar
  19. 19.
    Meduri GU, Kohler G, Headley S, Tolley E, Stentz F, Postlethwaite A (1995) Inflammatory cytokines in the BAL of patients with ARDS. Persistent elevation over time predicts poor outcome. Chest 108:1303–1314CrossRefPubMedGoogle Scholar
  20. 20.
    Sinclair SE, Bijoy J, Golden E, Carratu P, Umberger R, Meduri GU (2006) Interleukin-8 and soluble intercellular adhesion molecule-1 during acute respiratory distress syndrome and in response to prolonged methylprednisolone treatment. Minerva Pneumologica 45:93–104Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg and ESICM (outside the USA) 2014

Authors and Affiliations

  • Gianfranco Umberto Meduri
    • 1
    Email author
  • Mahmoud A. Eltorky
    • 2
  1. 1.Division of Pulmonary, Critical Care, and Sleep Medicine, Department of MedicineMemphis Veterans Affairs Medical CenterMemphisUSA
  2. 2.Surgical Pathology Division, Department of PathologyUniversity of Texas Medical BranchGalvestonUSA

Personalised recommendations